TP53 and sarcoma: This is somehow unexpected especially in the p53-dependent tumorigenesis model taking into account that stathmin is necessary for the survival of p53-null [37] and p53-mutated cells [36] and that human sarcomas and bladder carcinomas (Figure S1) frequently overexpress stathmin in the early stages of tumorigenesis.